A Phase I/II Study of Induction AMG 655 and Gemcitabine, Followed by AMG 655, Capecitabine and 3-D Conformal Radiation Therapy (3DCRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 21 Jun 2013
At a glance
- Drugs Conatumumab (Primary) ; Capecitabine; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 30 Mar 2010 Planned number of patients changed from 95 to 89 as reported by ClinicalTrials.gov.
- 30 Mar 2010 Planned end date changed from 1 Nov 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.